IPP Bureau
Volta Labs unveils push-button PCR-free whole genome sequencing kit
By IPP Bureau - February 26, 2026
The new solution combines Watchmaker Genomics’ high-performance NGS chemistry with Volta’s digital fluidics platform
Envoy Medical secures three new patents, bolstering cochlear implant leadership
By IPP Bureau - February 26, 2026
The new patents cover critical advancements in cochlear implant technology
Gilead to acquire Arcellx in $7.8 billion bet on next-generation CAR T therapy
By IPP Bureau - February 26, 2026
Arcellx develops innovative immunotherapies for cancer and other incurable diseases
Asahi Kasei to acquire German biopharmaceutical company Aicuris for €780 million
By IPP Bureau - February 26, 2026
Asahi Kasei is consistently pursuing its strategy of building a focused, sustainable specialty pharmaceutical platform for immunocompromised and medically complex patient groups
Alembic announces USFDA final approval for Efinaconazole Topical Solution, 10%
By IPP Bureau - February 25, 2026
Efinaconazole Topical Solution is indicated for the topical treatment of onychomycosis of the toenail(s) due to Trichophyton rubrum and Trichophyton mentagrophytes.
Caplin Steriles gets USFDA approval for Sodium Phosphate injection
By IPP Bureau - February 25, 2026
Sodium Phosphates Injection is indicated as a source of phosphorus, for addition to large volume intravenous fluids, to prevent or correct hypophosphatemia in patients with restricted or no oral intake
Indoco Remedies receives final ANDA approval from USFDA for Brivaracetam Oral Solution, 10 mg/mL
By IPP Bureau - February 25, 2026
Brivaracetam Oral Solution (10 mg/mL) is a prescription antiepileptic drug (anticonvulsant) used for treatment of partial-onset seizures in patients 1 month of age and older
Shilpa Biologicals and SteinCares ink strategic pact to bring biosimilars to Latin America
By IPP Bureau - February 25, 2026
New partnership combines Shilpa Biologicals’ development and manufacturing capabilities with SteinCares’ regional commercialization platform
CStone Pharmaceuticals’ Sugemalimab bags UK nods for Stage III NSCLC
By IPP Bureau - February 25, 2026
Sugemalimab, developed using CStone’s OmniRat transgenic platform, is a fully human IgG4 monoclonal antibody designed to minimize immunogenicity and toxicity
Formosa strikes exclusive deal with Arrotex to launch eye surgery drug in Australia & NZ
By IPP Bureau - February 25, 2026
The innovative eyedrop targets inflammation and pain following ocular surgery
Novo Nordisk unveils weight-loss data from REDEFINE 4 trial
By IPP Bureau - February 25, 2026
CagriSema produced a 23% weight loss at 84 weeks, versus 25.5% for tirzepatide
BNB Plus’ Biopharma subsidiary LineaRx lands major LineaDNA orders
By IPP Bureau - February 25, 2026
The announcement follows a record-setting $1.2 million accelerated LineaDNA order
Starton Therapeutics doses first patient in Phase 2a trial of STAR-LLD for multiple myeloma
By IPP Bureau - February 25, 2026
The Phase 2 trial, conducted through Starton’s Sargon Site Network, is expanding from two to six sites across the U.S.
UK nod to first-ever drug specifically for non-cystic fibrosis bronchiectasis
By IPP Bureau - February 25, 2026
NCFB is a chronic lung condition where damaged airways cause persistent coughing and mucus production
Lupin launches generic Brivaracetam oral solution in US to treat epilepsy
By IPP Bureau - February 25, 2026
Brivaracetam is the bioequivalent to Briviact Oral Solution, 10 mg/mL, of UCB
